FDA
-
-
-
-
-
-
-
Spruce Biosciences names medical affairs VP ahead of drug review
-
-
-
-
-
-
-
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
-
-
-
-
-
-
-
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Synd
-
-
-
-
-
-
-
Spruce Biosciences receives FDA breakthrough therapy designation for MPS IIIB
-
-
-
-
-
-
-
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203
-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Provides Corporate Update and Outlines Milestones for 2021
-
326,540 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

